Dr. Zoukaa B. Sargi, MD

Dr. Sargi practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Sargi's NPI, 1386854032, was assigned on May 23, 2007. Dr. Sargi graduated from St Joseph's University Medical School in 2000. Dr. Sargi holds Florida license ME 102892.

Dr. Sargi's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Sargi's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sargi practices. Vendor and product names are available with a free account.

Otolaryngology is Dr. Sargi's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Sargi is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dr. Sargi is licensed in Florida.

Dmand AI lists ear eustachian tube disorders, endoscopic sinus surgery, larynx and vocal cord disease and thyroid surgery among the conditions Dr. Sargi treats.

CMS data shows 220 Medicare services from Dr. Sargi across 6 procedure codes in 2024, for 143 Medicare patients. Medicare paid $39,699 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 143 Medicare patients who saw Dr. Sargi in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 24% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sargi's median patient age at 69, with 43% women.

In 2024, Dr. Sargi wrote 236 Medicare Part D claims for 79 patients. 92% of them were for generic drugs. CMS names the drug for 122 of them, across 5 drugs with 11 or more claims each, at $1,165 in total drug cost. In 2023, CMS named 103 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Sargi for performance year 2024, reported as part of a group. Dr. Sargi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sargi as offering telehealth.

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 82 papers to Dr. Sargi, published from 2007 to 2025. 2020 was the busiest year, with 12. The most frequent topics are Head and Neck Neoplasms, Endoscopy and Carcinoma, Squamous Cell. Dr. Sargi has published most often in Head Neck. Dr. Sargi's most frequent co-authors are Donald T. Weed, MD, Jason Martin Leibowitz, MD and Francisco J. Civantos, MD.

CMS Open Payments shows 24 general payments to Dr. Sargi from 8 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Medtronic USA, Inc. paid the most, $770.

Dmand AI lists 1 award for Dr. Sargi, most recently CMS Stage 1 EHR in 2013.

Dr. Sargi graduated from St Joseph's University Medical School in 2000. Dr. Sargi is a member of NHS, AHNS, ARS, NASBS and SUO.

Dr. Sargi is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.